Literatur
-
1
Cornberg M, Protzer U, Dollinger M M. et al .
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011].
Z Gastroenterol.
2007;
45
525-574
-
2
Perz J F, Armstrong G L, Farrington L A. et al .
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
J Hepatol.
2006;
45
529-538
-
3
Robert Koch Institut .
Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B. C und D im Jahr 2005.
Epidemiologisches Bulletin.
2006;
46
-
4
Rehermann B, Nascimbeni M.
Immunology of hepatitis B virus and hepatitis C virus infection.
Nat Rev Immunol.
2005;
5
215-229
-
5
Wiegand J, Hasenclever D, Tillmann H L.
Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.
Antivir Ther.
2008;
13
211-220
-
6
Lok A S, McMahon B J.
[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines].
Rom J Gastroenterol.
2004;
13
150-154
-
7
Sherman M, Peltekian K M, Lee C.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology.
1995;
22
432-438
-
8
Yang B, Zhang B, Xu Y. et al .
Prospective study of early detection for primary liver cancer.
J Cancer Res Clin Oncol.
1997;
123
357-360
-
9
Chen C J, Yang H I, Su J. et al .
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA.
2006;
295
65-73
-
10
Iloeje U H, Yang H I, Su J. et al .
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Gastroenterology.
2006;
130
678-686
-
11
Kallinowski B, Jilg W, Buchholz L. et al .
Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
Z Gastroenterol.
2003;
41
983-990
-
12
Tillmann H L, Hadem J, Leifeld L. et al .
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
J Viral Hepat.
2006;
13
256-263
-
13
Lau G K, Piratvisuth T, Luo K X. et al .
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2005;
352
2682-2695
-
14
Marcellin P, Lau G K, Bonino F. et al .
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2004;
351
1206-1217
-
15
ter Borg M J, Janssen H L.
Pegylated interferon-alpha2b and lamivudine in hepatitis B e antigen-positive chronic hepatitis B.
Ann Intern Med.
2005;
143
391-392
-
16
Chang T T, Gish R G, de Man R. et al .
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2006;
354
1001-1010
-
17
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
N Engl J Med.
2003;
348
800-807
-
18
Lai C L, Shouval D, Lok A S. et al .
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2006;
354
1011-1020
-
19
Liaw Y F, Gane E, Leung N. et al .
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B.
Gastroenterology.
2009;
136
486-495
-
20
Marcellin P, Chang T T, Lim S G. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
N Engl J Med.
2003;
348
808-816
-
21
Marcellin P, Heathcote E J, Buti M. et al .
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
N Engl J Med.
2008;
359
2442-2455
-
22
EASL-Jury .
EASL Clinical Practice Guidelines: Management of chronic hepatitis B.
J Hepatol.
2009;
50
-
23
Liaw Y F, Sung J J, Chow W C. et al .
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
N Engl J Med.
2004;
351
1521-1531
-
24
di Marco V, Marzano A, Lampertico P. et al .
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Hepatology.
2004;
40
883-891
-
25
Lampertico P, Vigano M, Manenti E. et al .
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Hepatology.
2005;
42
1414-1419
-
26
Cornberg M, Protzer U, Dollinger M M. et al .
The German guideline for the management of hepatitis B virus infection: short version.
J Viral Hepat.
2008;
15 (Suppl 1)
1-21
-
27
Rizzetto M.
Hepatitis D: virology, clinical and epidemiological aspects.
Acta Gastroenterol Belg.
2000;
63
221-224
-
28
Erhardt A, Knuth R, Sagir A. et al .
Socioepidemiological data on hepatitis delta in a German university clinic – increase in patients from Eastern Europe and the former Soviet Union.
Z Gastroenterol.
2003;
41
523-526
-
29
Moller B, Hopf U, Hoffmann H. et al .
[Frequency and clinical relevance of delta virus infection in HBsAg carriers in the Berlin area].
Z Gastroenterol.
1988;
26
314-321
-
30
Wedemeyer H, Heidrich B, Manns M P.
Hepatitis D virus infection – not a vanishing disease in Europe!.
Hepatology.
2007;
45
1331-1332
-
31
Liaw Y F, Chen T J, Chu C M. et al .
Acute hepatitis delta virus superinfection in patients with liver cirrhosis.
J Hepatol.
1990;
10
41-45
-
32
Wedemeyer H, Yurdaydin C, Dalekos G. et al .
72 week data of the HIDIT-1 trial: A multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis.
J Hepatol.
2007;
46
S4
Dr. med. Markus Cornberg
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
Medizinische Hochschule Hannover
Deutsche Leberstiftung
Carl-Neuberg-Straße 1
30625 Hannover
Email: Cornberg.Markus@mh-hannover.de
